Clinical evaluation of purified chick embryo cell rabies vaccine administered intradermally in animal exposures
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20180233Keywords:
PCECV, Rabipur, Vaxirab-N, Animal exposureAbstract
Background: In India, presently there are two purified chick embryo cell culture vaccines (PCECV) viz., Rabipur (Flury LEP strain) and Vaxirab – N (Pitman Moore strain) which are commonly used both in public as well as private sectors. The present study was conducted to assess the clinical efficacy in terms of safety, immunogenicity and survival status of both the PCECV administered animal exposures taking complete PEP at the anti-rabies clinic.
Methods: A longitudinal study was conducted at the anti-rabies clinic, Kempegowda Institute of Medical Sciences (KIMS), Bangalore, India. 86 suspect rabid dog bite cases attending clinic were enrolled and followed up for 1year. All the animal bite cases were given post exposure prophylaxis of full course of PCECV i.e. Rabipur or Vaxirab - N as per schedule intradermally using updated Thai Red Cross regimen. The rabies virus neutralizing antibody (RVNA) concentrations on days 14, 28, 90, and 180 were tested by modified rapid fluorescent focus inhibition test.
Results: Out of 86 study subjects, 43 subjects received Rabipur and another 43 subjects received Vaxirab –N vaccines. The incidence of adverse drug events (ADEs) was found to be 9.3%. All subjects had protective RVNA titers of ³0.5 IU/ml from day 14 till day 180. All the study subjects were healthy and alive after 6 months of completing PEP.
Conclusions: The currently available purified chick embryo cell culture rabies vaccines are safe, immunogenic and clinically effective for post exposure prophylaxis in animal bite cases, which will help in eliminating human rabies by 2020.
Metrics
References
WHO Expert Consultation on Rabies. Technical Report Series 982. World Health Organization, Geneva, 2013.
World Health Organization. Rabies vaccines: WHO position paper, Weekly Epidemiological Record, No. 32, 2010;85:309-20.
Elimination of dog-mediated human rabies from the world by 2030. World Health Organization, Geneva 2015. Available at: http://www.who.int/rabies/en. Accessed on 14 October 2016.
Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Rahman A et.al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis. 2007;11: 29-35.
WHO Expert Consultation on Rabies. Technical Report Series 931. World Health Organization, Geneva, 2005.
Weekly Epidemiological Record. World Health Organization (WHO) Rabies vaccines, WHO position paper. 2007;49/50(82):425-35.
Madhusudana SN, Sanjay TV, Mahendra BJ, Suja MS. Simulated post-exposure rabies vaccination with purified chick embryo cell vaccine using a modified Thai Red Cross regimen. Int J Infect Dis. 2004;8(3):175-9.
Sudarshan MK, Madhusudana SN, Mahendra BJ, Ashwathnarayana DH, Anand Giri MS, Popova O. Evaluation of a new five injection, two site, intradermal schedule for purified chick embryo cell rabies vaccine: A randomized, open label active controlled trial in healthy adult volunteers in India. Current Therap Res. 2005;66(4):323-4.
Khawplod P, Tantawichien T, Wilde H, Limusanno S, Tantawichien T, Saikasem A et al. Use of Rabies vaccines after Reconstitution and Storage. Clin Infect Dis. 2002;34:404-6.
Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P, et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for post exposure prophylaxis. Vaccine. 1994;12(6):508-12.
Madhusudana SN, Sanjay TV, Mahendra BJ, Sudarshan MK, Ashwath narayana DH, Anandgiri MS, et al. Comparison of safety and immunogenecity ofpurified chick embryo cell vaccine and purified verocell rabies vaccine using the Thai Red Cross intradermal regimen at a dose of 0.1 ml. Hum Vaccin. 2006;2(5):200-4.
Downloads
Published
How to Cite
Issue
Section
